Amanda Rose advises life sciences and technology companies with respect to corporate finance, SEC reporting and governance matters. Amanda has represented issuers and underwriters in a wide variety of public and private financing transactions, including initial public offerings, follow-on and secondary offerings, at-the-market offerings, PIPEs and preferred stock and debt financings. She also advises late-stage private companies with respect to general corporate governance and liquidity preparation and public companies on corporate and securities law compliance and disclosure matters, including corporate governance best practices, Exchange Act reporting obligations and stock exchange requirements. Chambers USA ranks Amanda as a top capital markets lawyer, with clients saying, "Amanda stands out as an exceptional young attorney with great judgment, poise, 24/7 availability and extreme attention to detail."
Prior to joining Fenwick & West, Amanda was an associate in the Corporate Group at Dorsey & Whitney LLP.
Amanda received her J.D., magna cum laude, from the Seattle University School of Law in 2009, where she was Associate Editor for the Seattle University Law Review. She earned her B.A., cum laude, in Political Science and Communication from the University of Washington in 2006.
Amanda is a member of the State Bar of Washington.
Eileen Shin is a Managing Director and Associate General Counsel in the investment bank of JPMorgan Chase & Co., where she provides legal and regulatory implementation support for equity, high yield debt and Latin America capital markets origination businesses as well as the global research department. She has served as a faculty member in previous Practicing Law Institute seminars on the topic of initial public offerings. She has been named in the Corporate Counsel 100 most influential in-house lawyers in business for Latin America. She and her legal colleagues have been recognized as the Equity In-House Legal Team of the Year by the International Financial Law Review in five of the past seven years. She has also participated in panel discussions relating to capital markets topics at National Asian Pacific American Bar Association conferences. Previously, she was a lawyer in the securities practice group at Simpson Thacher & Bartlett LLP. She is a graduate of Columbia Law School, where she was a Harlan Fiske Stone Scholar and an editor of the Human Rights Law Review. She holds a Master of Music degree in piano performance from the Eastman School of Music and a B.A. degree with honors in modern thought & literature from Stanford University. She was also a Rotary Foundation scholar for the study of piano performance in France. She and her husband have two children and live in the Upper West side of New York City.
Lee Stettner has worked on Wall Street for twenty five years in a variety of senior roles in both equity capital markets and corporate finance. Before joining Solebury, Lee was a Managing Director in Equity Capital Markets at J.P. Morgan where has responsible for both the Healthcare and Natural Resources sectors. He also served on the firm’s Equity Underwriting Commitment Committee which is responsible for evaluations all aspects of proposed equity transactions. Prior to joining J.P. Morgan, Lee was a Senior Managing Director and Global Head of Equity Capital Markets at Bear Stearns. From 2004-2007,
Lee was a Managing Director at Deutsche Bank where he a Managing Director and Head of Healthcare Investment Banking and Equity Capital Markets Group. Prior to Deutsche Bank, he was a Managing Director in the Equity Capital Markets Group at Credit Suisse First Boston, where he was responsible for origination in the Healthcare and Business Services sectors. Lee started his career at Dean Witter and Morgan Stanley, where he worked in the Healthcare Investment Banking Group.
Over the course of his career, Lee originated and bookran over 300 equity transactions, including landmark transactions for HCA, Alcon, Smith International, AEP, Laredo Petroleum, Antero Resources, AES, PPL, Premier Inc. Quintiles Weight Watchers, Quest Diagnostics, Progress Energy, LabCorp, Apache and Human Genome Sciences.
Lee graduated with a BA in Economics from Hamilton College and an MBA from the
Wharton School of Business of the University of Pennsylvania. Lee is a Board Member of the Mount Sinai Hospital Department of Medicine. Lee lives in Manhattan with his wife and two daughters.
Ravi is a Partner in PwC’s Deals practice focusing on Capital Markets & Accounting Advisory (CMAAS). He has 25 years of experience in the US and internationally, advising clients with respect to transformational capital markets transactions including IPOs, spin-offs, mergers and acquisitions, debt offerings and divestitures. The assistance includes advice on complex US GAAP, IFRS and SEC reporting matters. He serves some of our largest US based private equity clients with their acquisitions and dispositions/IPOs of US and European portfolio companies.
Ravi also spent 3 years in PwC’s National Office as part of PwC’s SEC Services practice. While at National, Ravi consulted with clients on a wide array of capital markets transactions, complex accounting and SEC matters and he also assisted clients with their pre-clearance of various issues with the US Securities and Exchange Commission.
Ravi is a frequent speaker on SEC reporting and accounting matters and has presented a number of webcasts on IPOs, Corporate Divestitures/Carve-outs, and Mergers and Acquisitions. He is an author and contributor on thought leadership related to divestitures and business combinations and has appeared in PwC’s CFOdirect network videos on various SEC reporting related topics. He has worked for PricewaterhouseCoopers in Amsterdam, Netherlands and London, United Kingdom.
Areas of focus include: IPOs, spin-offs, 144a debt offerings, carve-outs, mergers and acquisitions/business combinations, IFRS/US GAAP conversions, SEC reporting and project management advice associated with all of the above.
Robert (Rob) Freedman is co-chair of the Securities & Corporate Finance group and provides corporate and securities law services to late stage and public technology and life sciences companies. He leads initial public offerings and follow-on offerings of equity and debt, and focuses on advising boards and management on corporate and securities law compliance and disclosure matters. Rob has represented issuers and underwriters in securities offerings by public companies for over 20 years. Rob also concentrates on mergers and acquisitions and private financings for public companies.
Rob has been recommended by The Legal 500 for his individual practice and role as co-chair of Fenwick & West’s corporate and securities practice, which was recognized as a team of “highly knowledgeable and flexible technology sector specialists.”
Representative Initial Public Offering Experience:
Cowen and Company
Piper Jaffray & Co.
Silver Spring Networks
Representative M&A and Tender Offer Experience:
OncoGenex Pharmaceuticals’ merger with Achieve Life Science
Castlight Health’s acquisition of Jiff
Corium’s acquisition by Gurnet Point Capital
KalVista Pharmaceuticals’ acquisition of Carbylan Therapeutics
DexCom’s acquisition of SweetSpot Diabetes Care
Zappos.com’s acquisition by Amazon.com
Alpha Innotech’s acquisition by Cell Biosciences
Data Domain’s acquisition by EMC
Cisco Systems’ acquisition of WebEx Communications
Macromedia’s merger with Adobe
Rob is a member of the State Bars of California, Idaho and Washington. He received his A.B. degree in biochemistry and history in 1987 from Bowdoin College where he graduated summa cum laude and Phi Beta Kappa. He received his J.D. degree, with distinction, in 1993 from Stanford University.
Rob is the co-chair for the Practising Law Institute’s “How to Prepare an Initial Public Offering” program. Prior to law school, Rob was a banker for Manufacturers Hanover Trust in New York.
Sophia Hudson is a capital markets partner in the New York office of Kirkland & Ellis LLP. Sophia advises issuers and underwriters on capital markets transactions, including initial public offerings and follow-on equity offerings, public and private high-yield, investment-grade and convertible debt offerings and private placements of equity and convertible securities for early stage companies. She also counsels her corporate clients, including management teams and boards of directors, on governance, corporate and securities law matters.
Her experience ranges across a variety of industries, including consumer goods, financials, industrials, life sciences, mining, retail, specialty pharmaceuticals and technology. She has represented all the major U.S. investment banks.
Sophia has been recognized as a leading capital markets attorney by major legal publications, including named a “Rising Star” by New York Law Journal in 2017 and by Law360 for Life Sciences in 2016.
Sophia was a member of the Partnership for New York City 2016-2017 class of David Rockefeller Fellows. She has served as the co-chair of Practising Law Institute’s “How to Prepare an Initial Public Offering” since 2015. Sophia received her J.D. from the University of Michigan Law School and her A.B. from Princeton University.
Ms. Dircks joined Morgan Stanley in 2006. She is an Executive Director in the Equity Capital Markets Department and has been with the firm for 12 years; she has held positions across the Equity Syndicate desk and Healthcare Capital Markets.